sa

[ASAP] Discovery of (2<italic toggle="yes">R</italic>)-<italic toggle="yes">N</italic>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<italic toggle="yes">H</italic>-indol-7

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01392




sa

[ASAP] Correction to Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00599




sa

[ASAP] Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01336




sa

[ASAP] Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00202




sa

[ASAP] Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00015




sa

[ASAP] Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01936




sa

[ASAP] Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00101




sa

[ASAP] Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00491




sa

[ASAP] Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01937




sa

[ASAP] Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources<subtitle>Miniperspective</subtitle>

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02126




sa

[ASAP] Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00339




sa

[ASAP] A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00011




sa

[ASAP] Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00395




sa

[ASAP] p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02038




sa

[ASAP] Both <sc>d</sc>- and <sc>l</sc>-Glucose Polyphosphates Mimic <sc>d</sc>-<italic toggle="yes">myo</italic>-Inositol 1,4,5-Trisphosphate: New Synthetic Agonists and Partial Agonists at the Ins

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00215




sa

[ASAP] Structural Fingerprints of an Intact Monoclonal Antibody Acquired under Formulated Storage Conditions via <sup>15</sup>N Direct Detection Nuclear Magnetic Resonance

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00231




sa

[ASAP] Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00245




sa

[ASAP] Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00021




sa

[ASAP] Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00442




sa

[ASAP] Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00337




sa

[ASAP] Discovery of <italic toggle="yes">N</italic>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<italic toggle="yes">H</italic>-pyrrolo[2,3-<italic toggle=&q

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00628




sa

[ASAP] Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00082




sa

[ASAP] Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to <italic toggle="yes">In Vivo</italic> Studies

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00431




sa

[ASAP] Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00192




sa

[ASAP] Exploration of the Structural Space in 4(3<italic toggle="yes">H</italic>)-Quinazolinone Antibacterials

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00153




sa

[ASAP] Drug Research Meets Network Science: Where Are We?

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01989




sa

[ASAP] Discovery and Optimization of Glucose Uptake Inhibitors

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02153




sa

[ASAP] Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00441




sa

[ASAP] Discovery of a Cyclic Choline Analog That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00005




sa

[ASAP] Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00601




sa

[ASAP] Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00664




sa

[ASAP] Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-<italic toggle="yes">a</italic>]pyridines against the 1A Family

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00686




sa

[ASAP] Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00118




sa

[ASAP] Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00116




sa

[ASAP] Glycans Meet Sphingolipids: Structure-Based Design of Glycan Containing Analogues of a Sphingosine Kinase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00665




sa

[ASAP] Peptoid NPhe<sup>4</sup> in AGRP-Based c[Pro<sup>1</sup>-Arg<sup>2</sup>-Phe<sup>3</sup>-Phe<sup>4</sup>-Xxx<sup>5</sup>-Ala<sup>6</sup>-Phe<sup>7</sup>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00641




sa

[ASAP] Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00075




sa

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




sa

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




sa

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




sa

[ASAP] Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00041




sa

[ASAP] Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-Dimensional Character

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00039




sa

[ASAP] Characterization of an Alginate Encapsulated LS180 Spheroid Model for Anti-colorectal Cancer Compound Screening

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00076




sa

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




sa

[ASAP] Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00625




sa

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




sa

[ASAP] Assembling Pharma Resources to Tackle Diseases of Underserved Populations

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00051




sa

[ASAP] Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00639




sa

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




sa

[ASAP] Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00063